126 related articles for article (PubMed ID: 38530204)
41. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.
Stanke F; Pallenberg ST; Tamm S; Hedtfeld S; Eichhorn EM; Minso R; Hansen G; Welte T; Sauer-Heilborn A; Ringshausen FC; Junge S; Tümmler B; Dittrich AM
Front Pharmacol; 2023; 14():1114584. PubMed ID: 36778025
[No Abstract] [Full Text] [Related]
42. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Kapouni N; Moustaki M; Douros K; Loukou I
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
[TBL] [Abstract][Full Text] [Related]
43. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M
Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253
[No Abstract] [Full Text] [Related]
44. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One
Goralski JL; Hoppe JE; Mall MA; McColley SA; McKone E; Ramsey B; Rayment JH; Robinson P; Stehling F; Taylor-Cousar JL; Tullis E; Ahluwalia N; Chin A; Chu C; Lu M; Niu T; Weinstock T; Ratjen F; Rosenfeld M
Am J Respir Crit Care Med; 2023 Jul; 208(1):59-67. PubMed ID: 36921081
[No Abstract] [Full Text] [Related]
45. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
46. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
[TBL] [Abstract][Full Text] [Related]
47. S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy
Allan KM; Astore MA; Fawcett LK; Wong SL; Chen PC; Griffith R; Jaffe A; Kuyucak S; Waters SA
Front Pediatr; 2022; 10():1062766. PubMed ID: 36467478
[TBL] [Abstract][Full Text] [Related]
48. Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis-a real world study.
Appelt D; Steinkamp G; Sieber S; Ellemunter H
Front Pharmacol; 2023; 14():1125853. PubMed ID: 36969845
[TBL] [Abstract][Full Text] [Related]
49. Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.
Steinack C; Ernst M; Beuschlein F; Hage R; Roeder M; Schuurmans MM; Schmid C; Gaisl T
J Cyst Fibros; 2023 Jul; 22(4):722-729. PubMed ID: 36669960
[TBL] [Abstract][Full Text] [Related]
50. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.
Keogh RH; Cosgriff R; Andrinopoulou ER; Brownlee KG; Carr SB; Diaz-Ordaz K; Granger E; Jewell NP; Lewin A; Leyrat C; Schlüter DK; van Smeden M; Szczesniak RD; Connett GJ
Thorax; 2022 Sep; 77(9):873-881. PubMed ID: 34556554
[TBL] [Abstract][Full Text] [Related]
51. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
Wright BA; Ketchen NK; Rasmussen LN; Bartels AR; Singh SB
Pediatr Pulmonol; 2022 Mar; 57(3):655-657. PubMed ID: 34859619
[TBL] [Abstract][Full Text] [Related]
52. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
53. Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.
Park J; Walsh A; Kerr S; Woodland C; Southward S; Deakin M; Senniappan S; Thursfield R
Horm Res Paediatr; 2024; 97(1):94-98. PubMed ID: 37040724
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.
Xu W; Wu T; Zhou Z; Zuo Z
Front Pharmacol; 2023; 14():1275470. PubMed ID: 38186649
[No Abstract] [Full Text] [Related]
55. Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis.
Welsner M; Schulte T; Dietz-Terjung S; Weinreich G; Stehling F; Taube C; Strassburg S; Schoebel C; Sutharsan S
Respiration; 2022; 101(8):766-774. PubMed ID: 35598598
[TBL] [Abstract][Full Text] [Related]
56. Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study.
Lopes K; Custódio C; Lopes C; Bolas R; Azevedo P
J Bras Pneumol; 2023; 49(2):e20220312. PubMed ID: 36820745
[TBL] [Abstract][Full Text] [Related]
57. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
[TBL] [Abstract][Full Text] [Related]
58. Upper Airway Disease in Adults with Cystic Fibrosis in the Era of CFTR Modulators.
Uyttebroek S; Dupont L; Jorissen M; Van Gerven L
Laryngoscope; 2023 Nov; 133(11):2898-2909. PubMed ID: 36912358
[TBL] [Abstract][Full Text] [Related]
59. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers.
Ciciriello F; Bijvelds MJC; Alghisi F; Meijsen KF; Cristiani L; Sorio C; Melotti P; Fiocchi AG; Lucidi V; De Jonge HR
J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455747
[TBL] [Abstract][Full Text] [Related]
60. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.
Dagenais RVE; Su VCH; Quon BS
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
